Riyadh – Bayer and Alpha Pharma have signed a Memorandum of Understanding (MoU) to establish local production of Aspirin Protect in Saudi Arabia, marking a significant step toward the Kingdom’s pharmaceutical self-sufficiency goals under Vision 2030. The manufacturing facility will be located at Alpha Pharma’s modern production center in King Abdullah Economic City (KAEC), with operations expected to begin in 2028. This partnership aligns with the Local Content and Government Procurement Authority’s initiatives to strengthen domestic healthcare resilience.

Key Takeaways

  • Aspirin Protect manufacturing will commence in Saudi Arabia in 2028 through the Bayer-Alpha Pharma partnership
  • The initiative supports Vision 2030’s Health Sector Transformation Program and reduces import dependency for cardiovascular treatments
  • Local production introduces international pharmaceutical expertise and quality standards to the Saudi healthcare ecosystem
  • The partnership addresses cardiovascular disease (CVD) as a national health priority with sustainable access to essential medicines

Why This Partnership Matters for Vision 2030

Aspirin Protect is Bayer’s cardiovascular brand, with over 127 years of clinical use in heart disease prevention and treatment. According to Bayer, CVD remains a significant public health challenge in Saudi Arabia. By localizing production, the partnership directly supports the Kingdom’s Health Sector Transformation Program—a central pillar of Vision 2030—while reducing reliance on imported medicines.

Maged El Shazly, Managing Director of Bayer Saudi Arabia and Country Commercial Lead for Bayer Consumer Health, stated: “The local manufacturing of Aspirin Protect represents a step toward realizing Vision 2030 ambitions. By integrating international quality with local capabilities, we ensure reliable access to essential medicines where and when needed most.”

Pharmaceutical Localization and Economic Growth

Beyond public health benefits, the partnership contributes to Saudi Arabia’s economic diversification strategy. Bayer will transfer advanced manufacturing technology and expertise to Alpha Pharma’s operations. This capability transfer equips Saudi Arabia’s pharmaceutical sector to meet international quality standards while building a skilled, local workforce.

Yasser Naghi, Chairman of Alpha Pharma, said: “This partnership marks a significant milestone for Saudi pharmaceutical expertise. By supporting localization of Aspirin Protect, we reinforce healthcare system resilience while advancing the national objective of pharmaceutical self-sufficiency.”

Building on Years of Health Cooperation

The MoU builds on Bayer’s three-year collaboration with Saudi Arabia’s Ministry of Health on cardiovascular disease awareness and screening programs. The shift to local manufacturing represents an escalation of this commitment—from public education to supply chain security.

According to the companies, this addresses a critical gap: ensuring consistent availability of a life-saving product through domestic production rather than imports. Production is expected to reach full operational capacity by 2028.

What’s Next

Bayer and Alpha Pharma will now work through regulatory approval processes and facility preparation. The 2028 production timeline allows sufficient lead time for infrastructure development, regulatory compliance, and workforce training. This partnership signals a broader trend in Vision 2030: deepening public-private collaboration to localize critical healthcare technologies.

The initiative demonstrates how international pharmaceutical leaders can support Saudi Arabia’s transition toward a more self-reliant, regionally competitive healthcare manufacturing sector.